We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Targeted Fluorescent-Imaging Compound Detects Viable Cancer Cells

By LabMedica International staff writers
Posted on 19 Jan 2009
A fluorescent-imaging compound is turned on only when it is inside a living cell and stops fluorescing when the cell dies or becomes damaged. More...
The compound can be engineered to target specific types of cancer cells.

The new compound enabled scientists to visualize viable breast cancer cells that have spread to the lungs in mice. The compound binds to a protein called HER2, which is found on the surface of some breast cancer cells, and it glows, or fluoresces, only when taken into living cells. This method of targeting and activation allowed the scientists to detect specific types of live cancer cells in a mouse model of breast cancer.

Previously developed fluorescent compounds that are activated inside the body's cells have the limitation that once turned on they continue to fluoresce even after they diffuse to new locations. This makes it very difficult to distinguish viable tumor cells from normal tissue, dead, or damaged tumor cells.

The investigation took place at the National Cancer Institute (NCI), part of the US National Institutes of Health (Bethesda, MD, USA) and in Japan. The scientific team that created the imaging compound was led by Hisataka Kobayashi, M.D., Ph.D., from NCI's Center for Cancer Research (CCR), in collaboration with Yasuteru Urano, Ph.D., from the University of Tokyo (Japan).

"These [fluorescing-imaging] compounds may allow clinicians to monitor a patient's response to cancer therapy by allowing them to visualize whether a drug hits its target and whether hitting the target leads to shrinkage of the tumor," said Dr. Kobayashi. He added, "Our design concept is very versatile and can be used to detect many types of cancer. Unlike other activatable fluorescent compounds, our compound consists of a targeting agent and a fluorescing agent that act independently. We can target the fluorescing agent to different types of cancer cells by using any antibody or molecule that is internalized by the targeted cells after it binds to the cell's surface proteins."

The new compound was described online in Nature Medicine on December 7, 2008.

Related Links:

US National Institutes of Health
University of Tokyo



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
New
Gold Member
Collection and Transport System
PurSafe Plus®
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.